The protozoan parasite Trypanosoma cruzi causes Chagas disease, an important public health problem throughout Latin America. Current therapeutic options are characterised by limited efficacy, long treatment regimens and frequent toxic side-effects. Advances in this area have been compromised by gaps... in our knowledge of disease pathogenesis, parasite biology and drug activity. Nevertheless, several factors have come together to create a more optimistic scenario. Drug-based research has become more systematic, with increased collaborations between the academic and commercial sectors, often within the framework of not-for-profit consortia. High-throughput screening of compound libraries is being widely applied, and new technical advances are helping to streamline the drug development pipeline. In addition, drug repurposing and optimisation of current treatment regimens, informed by laboratory research, are providing a basis for new clinical trials. Here, we will provide an overview of the current status of Chagas disease drug development, highlight those areas where progress can be expected, and describe how fundamental research is helping to underpin the process.
more
Standard Treatment Guideline
Available in English, French, Spanish, Russian, Chinese, Arabic and Portugues
Video about asthma:
What is asthma?
Lets learn together about asthma as Dr.Shema Christine explains to depth about asthma
The purpose of this document is to share good practices and processes concerning the inclusion of disability issues in HIV policy and programming, drawing on specific experiences in Senegal, Ethiopia, Kenya, Rwanda and Cambodia and on lessons learned at international AIDS conferences.
These guidelines group all recommendations on TB care and support in one document and are complemented by an operational handbook. The guidelines are to be used primarily by national TB programmes, or their equivalents in Ministries of Health, stakeholders and technical organizations working on... TB care in the public and private sectors and in the community.
more
Nguyen HH et al. Journal of the International AIDS Society 2018, 21:e25151 http://onlinelibrary.wiley.com/doi/10.1002/jia2.25151/full | https://doi.org/10.1002/jia2.25151
Child Friendly Spaces (CFSs) are used by humanitarian agencies as a means to promote protection and psychosocial wellbeing for children in emergency settings. World Vision International together with Columbia University is conducting a series of studies to investigate the effectiveness of CFSs in va...rious humanitarian contexts in order to document evidence of the positive effects they have in relation to child wellbeing and protection, to identify good practice in their design and implementation and to develop improved monitoring and evaluation approaches for CFSs. The case studies have so far all been focused on refugee settings and while internally displaced populations (IDPs) share many of the circumstances and challenges of refugees it was decided that CFSs operating in IDP settings warrant a particular investigation in order to assess their relevance and effectiveness in promoting child protection and psychosocial wellbeing. This report thus presents the findings from an IDP focused study on CFS effectiveness in three camps near Goma, eastern Democratic Republic of Congo (DRC).
more
Standard Treatment Guideline
Le constat est accablant : toutes les 90 secondes une femme meurt suite à des complications qui interviennent durant la grossesse, l’accouchement ou les six semaines suivant celui-ci. 90% de ces décès ont lieu dans les pays en développement. La mortalité maternelle est parmi les problèmes de... santé qui révèlent le plus large fossé entre riches et pauvres. C’est pour cette raison que sa réduction est devenue l’un des huit Objectifs du Millénaire pour le Développement (OMD) qui se donne pour but de réduire de trois quarts, entre 1990 et 2015, le taux de mortalité maternelle1. Depuis 1990, on estime aujourd’hui que les décès maternels ont reculé de 45% à l’échelle mondiale….
more
Expert opinion of the European Tuberculosis Laboratory Initiative core group members for the WHO European Region.